Celularity, a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group, an international import, export and trading company, have entered into an exclusive distribution agreement with the Tamer Group, a leading Middle East healthcare distribution company.
Under the agreement, Tamer will be the exclusive distributor for Celularity’s branded regenerative biomaterial products in Saudi Arabia.
Through the agreement, CH Trading Group will distribute to more than 100 countries that are members of or associated with the following intergovernmental organizations.
Ayman Tamer Chairman & Managing Partner Tamer Group
“Celularity’s Halal-Certified regenerative biomaterial products enable Tamer to realize our fundamental ambitions of contributing to personal wellness and public health, as well as supporting Saudi Arabia’s Vision 2030 plan for healthcare innovation and development.”
“Today’s announcement marks an important next step in Celularity’s Islamic Markets strategy, to bring our innovative Halal-Certified, under globally recognized Circle H International Standards, regenerative biomaterial products to treat degenerative disease into the Saudi Arabia market. This is an important validation of our unique business model, which creates multiple cellular therapeutics, advanced biomaterials and derivatives from the single source material, and our proprietary manufacturing processes,” said Celularity’s CEO, Chairman and Founder, Mr. Robert J. Hariri, M.D., Ph.D.
It is anticipated that these biomaterial products are to become available in Saudi Arabia in 2023 following receipt of approval from the Saudi Food and Drug Authority. Tamer is expected to be Celularity’s and CH Group’s local strategic partner for Celularity’s Lifebank business model for placenta and cord blood banking, as well as for a new Serum Banking business and other potential research and development collaborations.
